PL2470546T3 - Związki heksahydrooksazynopterydynowe do zastosowania jako inhibitory MTOR - Google Patents
Związki heksahydrooksazynopterydynowe do zastosowania jako inhibitory MTORInfo
- Publication number
- PL2470546T3 PL2470546T3 PL10749736T PL10749736T PL2470546T3 PL 2470546 T3 PL2470546 T3 PL 2470546T3 PL 10749736 T PL10749736 T PL 10749736T PL 10749736 T PL10749736 T PL 10749736T PL 2470546 T3 PL2470546 T3 PL 2470546T3
- Authority
- PL
- Poland
- Prior art keywords
- hexahydrooxazinopteridine
- compounds
- mtor inhibitors
- mtor
- inhibitors
- Prior art date
Links
- QCXCHXZKOUVUJT-UHFFFAOYSA-N 3,4,4a,5,5a,8-hexahydro-1H-oxazino[3,4-g]pteridine Chemical class N1OCCC2C1=NC1=CN=CNC1N2 QCXCHXZKOUVUJT-UHFFFAOYSA-N 0.000 title 1
- 229940124302 mTOR inhibitor Drugs 0.000 title 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23806409P | 2009-08-28 | 2009-08-28 | |
| US31360810P | 2010-03-12 | 2010-03-12 | |
| EP10749736.4A EP2470546B1 (en) | 2009-08-28 | 2010-08-26 | Hexahydrooxazinopteridine compounds for use as mtor inhibitors |
| PCT/US2010/046839 WO2011025889A1 (en) | 2009-08-28 | 2010-08-26 | HEXAHYDROOXAZINOPTERINE COMPOUNDS FOR USE AS mTOR INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2470546T3 true PL2470546T3 (pl) | 2013-12-31 |
Family
ID=42768136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10749736T PL2470546T3 (pl) | 2009-08-28 | 2010-08-26 | Związki heksahydrooksazynopterydynowe do zastosowania jako inhibitory MTOR |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8163755B2 (pl) |
| EP (1) | EP2470546B1 (pl) |
| JP (1) | JP2013503183A (pl) |
| AR (1) | AR077974A1 (pl) |
| DK (1) | DK2470546T3 (pl) |
| ES (1) | ES2432315T3 (pl) |
| HR (1) | HRP20130951T1 (pl) |
| PL (1) | PL2470546T3 (pl) |
| PT (1) | PT2470546E (pl) |
| SI (1) | SI2470546T1 (pl) |
| TW (1) | TW201119656A (pl) |
| UY (1) | UY32863A (pl) |
| WO (1) | WO2011025889A1 (pl) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2448938B9 (en) | 2009-06-29 | 2015-06-10 | Incyte Corporation | Pyrimidinones as pi3k inhibitors |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| CN102762568A (zh) * | 2009-12-23 | 2012-10-31 | 伊兰药品公司 | 作为polo样激酶的抑制剂的蝶啶酮 |
| EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| JP5961187B2 (ja) | 2010-12-20 | 2016-08-02 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン |
| WO2012104776A1 (en) | 2011-01-31 | 2012-08-09 | Novartis Ag | Novel heterocyclic derivatives |
| TWI592411B (zh) | 2011-02-23 | 2017-07-21 | 英特爾立秦有限責任公司 | 激酶抑制劑之組合及其用途 |
| JP5931933B2 (ja) | 2011-02-25 | 2016-06-08 | 武田薬品工業株式会社 | Ｎ−置換オキサジノプテリジンおよびオキサジノプテリジノン |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| MX389479B (es) | 2011-09-02 | 2025-03-20 | Incyte Holdings Corp | Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k) |
| SG11201401716XA (en) | 2011-10-28 | 2014-05-29 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| US20150182490A1 (en) | 2012-06-26 | 2015-07-02 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| CA2881322A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| TWI736135B (zh) | 2013-03-01 | 2021-08-11 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| EP2976086B1 (en) | 2013-03-22 | 2020-10-14 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| AU2014293013A1 (en) | 2013-07-26 | 2016-03-17 | Race Oncology Ltd. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| CN105636962B (zh) * | 2013-10-15 | 2017-10-13 | 靳博涵 | 新型化合物、用途及其制备方法 |
| CA3158254C (en) | 2014-04-08 | 2024-05-21 | Incyte Corporation | Treatment of b-cell malignancies by a combination jak and pi3k inhibitors |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| SG10201912302VA (en) | 2015-02-27 | 2020-02-27 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
| US20160362424A1 (en) | 2015-05-11 | 2016-12-15 | Incyte Corporation | Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| KR102017676B1 (ko) * | 2018-03-09 | 2019-09-03 | 연세대학교 원주산학협력단 | 익상편 예방 및 치료용 조성물 |
| IL278889B2 (en) | 2018-06-01 | 2025-11-01 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| WO2020076728A1 (en) * | 2018-10-08 | 2020-04-16 | Takeda Pharmaceutical Company Limited | SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR |
| GB202415232D0 (en) | 2024-10-16 | 2024-11-27 | Nacamed As | Composition |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7189851B2 (en) | 2002-03-06 | 2007-03-13 | Smithkline Beecham Corporation | Condensed heterocyclic compounds as calcitonin agonists |
| GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| US8911498B2 (en) | 2005-02-10 | 2014-12-16 | DePuy Synthes Products, LLC | Intervertebral prosthetic disc |
| WO2006086464A2 (en) | 2005-02-10 | 2006-08-17 | Bristol-Myers Squibb Company | Dihydroquinazolinones as 5ht modulators |
| US20090325957A1 (en) | 2006-08-24 | 2009-12-31 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| KR101601332B1 (ko) | 2007-10-05 | 2016-03-08 | 센화 바이오사이언시즈 인코포레이티드 | 퀴놀론 유사체 및 이와 관련된 방법 |
| US20090149458A1 (en) * | 2007-11-27 | 2009-06-11 | Wyeth | PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS |
| BR112013008526A2 (pt) * | 2010-10-08 | 2016-07-12 | Elan Pharm Inc | inibidores de quinase do tipo polo |
-
2010
- 2010-08-26 AR ARP100103122A patent/AR077974A1/es unknown
- 2010-08-26 US US12/869,452 patent/US8163755B2/en active Active
- 2010-08-26 DK DK10749736.4T patent/DK2470546T3/da active
- 2010-08-26 WO PCT/US2010/046839 patent/WO2011025889A1/en not_active Ceased
- 2010-08-26 SI SI201030392T patent/SI2470546T1/sl unknown
- 2010-08-26 HR HRP20130951AT patent/HRP20130951T1/hr unknown
- 2010-08-26 ES ES10749736T patent/ES2432315T3/es active Active
- 2010-08-26 PT PT107497364T patent/PT2470546E/pt unknown
- 2010-08-26 EP EP10749736.4A patent/EP2470546B1/en not_active Not-in-force
- 2010-08-26 JP JP2012526992A patent/JP2013503183A/ja not_active Ceased
- 2010-08-26 PL PL10749736T patent/PL2470546T3/pl unknown
- 2010-08-27 TW TW099128976A patent/TW201119656A/zh unknown
- 2010-08-27 UY UY0001032863A patent/UY32863A/es not_active Application Discontinuation
-
2012
- 2012-03-26 US US13/429,865 patent/US8268819B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT2470546E (pt) | 2013-10-14 |
| US8268819B2 (en) | 2012-09-18 |
| US20110053921A1 (en) | 2011-03-03 |
| JP2013503183A (ja) | 2013-01-31 |
| TW201119656A (en) | 2011-06-16 |
| ES2432315T3 (es) | 2013-12-02 |
| UY32863A (es) | 2011-03-31 |
| US20120178924A1 (en) | 2012-07-12 |
| AR077974A1 (es) | 2011-10-05 |
| EP2470546A1 (en) | 2012-07-04 |
| HRP20130951T1 (hr) | 2013-11-22 |
| SI2470546T1 (sl) | 2013-12-31 |
| US8163755B2 (en) | 2012-04-24 |
| EP2470546B1 (en) | 2013-07-24 |
| WO2011025889A1 (en) | 2011-03-03 |
| DK2470546T3 (da) | 2013-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2470546T1 (sl) | Spojine heksahidrooksazinopteridina za uporabo kot MTOR inhibitorji | |
| IL216145A0 (en) | Dihydropyrimidinones for use as bace2 inhibitors | |
| IL215297A0 (en) | Imidazopyrazines for use as kinase inhibitors | |
| ZA201202703B (en) | Synthetic methods for spiro-oxindole compounds | |
| GB0906472D0 (en) | New compounds | |
| GB0906470D0 (en) | New compounds | |
| IL220154A0 (en) | Novel pyrimidine compounds as mtor and pi3k inhibitors | |
| ZA201206410B (en) | Polyheterocylic compounds highly potent as hcv inhibitors | |
| EP2393493A4 (en) | LINKS | |
| IL219248A0 (en) | Compounds | |
| GB0907515D0 (en) | Compounds | |
| ZA201400374B (en) | 4-piperidinyl compounds for use as tankyrase inhibitors | |
| EP2416657A4 (en) | COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF | |
| IL218915A0 (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| ZA201108131B (en) | Dihydroorotate- dehydrogenasee inhibitors as virostatic compounds | |
| EP2519508A4 (en) | METALLO ENZYME INHIBITOR COMPOUNDS | |
| GB0915892D0 (en) | Compounds | |
| IL220701A0 (en) | Tricyclic compounds for use as kinase inhibitors | |
| GB0900388D0 (en) | New compounds | |
| GB0903493D0 (en) | New compounds | |
| IL217049A0 (en) | 3-phenoxymethylpyrrolidine compounds | |
| GB201004372D0 (en) | Compounds for purification | |
| AP2909A (en) | Pyrazinoisoquinoline Compounds | |
| EP2443115A4 (en) | COMPOUNDS | |
| GB201004308D0 (en) | New inhibitor compounds |